>Mercado de nefropatía por IgA en Asia-Pacífico, por tipo de enfermedad (nefropatía por IgA primaria y nefropatía por IgA secundaria), síntomas (hematuria, proteinuria, edema y otros), tipo (diagnóstico y tratamiento), tipo de población (pediatría y adultos), vía de administración (oral, parenteral y otros), usuario final (hospitales, clínicas, atención médica domiciliaria y otros), canal de distribución (licitación directa, farmacia hospitalaria, farmacia minorista, farmacia en línea y otros), país (Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas, Vietnam, resto de Asia-Pacífico), tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado: mercado de nefropatía por IgA en Asia y el Pacífico
Se espera que el mercado de la nefropatía por IgA gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 20,0% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 308,79 millones para 2028. Los crecientes descubrimientos de fármacos para la nefropatía por IgA son los principales impulsores que impulsan la demanda del mercado en el período de pronóstico. El aumento del trastorno de nefropatía por IgA conduce a un aumento de la carga de la enfermedad, lo que aumentará la demanda de productos de diagnóstico y tratamiento, por lo que actúa como impulsor del crecimiento del mercado de la nefropatía por IgA.
La nefropatía por IgA, también conocida como enfermedad de Berger, es una enfermedad renal causada por la acumulación de depósitos de IgA en los riñones, que provocan inflamación y daño a los tejidos renales. Los anticuerpos como la IgA son proteínas producidas por el sistema inmunológico para proteger al cuerpo de sustancias extrañas, incluidas bacterias y virus. La complicación de esta enfermedad es la enfermedad renal terminal (ESKD), que luego requiere diálisis para su tratamiento.
El aumento de los fármacos en desarrollo dirigidos a la nefropatía por IgA permite que el candidato potencial demuestre la eficacia del tratamiento de la nefropatía por IgA, por lo que actúa como impulsor del mercado de la nefropatía por IgA. El costo del tratamiento de la nefropatía por IgA aumenta la carga financiera del paciente en caso de que no haya reembolso, por lo que actúa como una restricción para el crecimiento del mercado de la nefropatía por IgA. La colaboración de los actores del mercado para el desarrollo de fármacos aumenta la presencia y la innovación en el mercado, por lo que actúa como una oportunidad para el crecimiento del mercado de la nefropatía por IgA. Los efectos secundarios asociados con el tratamiento de la nefropatía por IgA y el impacto de la COVID-19 en el mercado de fármacos inmunosupresores actúan como un desafío para el crecimiento del mercado de la nefropatía por IgA.
El informe de mercado de nefropatía por IgA proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado de nefropatía por IgA, comuníquese con Data Bridge Market Research para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de la nefropatía por IgA
El mercado de la nefropatía por IgA está segmentado en función del tipo de enfermedad, los síntomas, el tipo, el tipo de población, la vía de administración, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
- Según el tipo de enfermedad, el mercado de la nefropatía por IgA se segmenta en nefropatía por IgA primaria y nefropatía por IgA secundaria. En 2021, se espera que el segmento de nefropatía por IgA primaria domine el mercado porque la incidencia de la nefropatía por IgA primaria es mayor y se puede diagnosticar fácilmente mediante análisis de sangre u orina.
- En función de los síntomas, el mercado de la nefropatía por IgA se segmenta en hematuria , proteinuria, edema y otros. En 2021, se espera que el segmento de hematuria domine el mercado, ya que es el parámetro más común y utilizado con frecuencia para el examen clínico y se detecta por la cantidad de sangre en la orina que muestra la aparición de la enfermedad en el riñón.
- Según el tipo, el mercado de la nefropatía por IgA se segmenta en diagnóstico y tratamiento. En 2021, se espera que el segmento de diagnóstico domine el mercado debido a que, antes de administrar el tratamiento, es necesario detectar y rastrear adecuadamente la nefropatía por IgA, lo que solo es posible mediante la detección primaria, como análisis de sangre y orina, y la detección confirmatoria mediante biopsia renal, que son el factor principal para que este segmento domine.
- Según el tipo de población, el mercado de la nefropatía por IgA se segmenta en pediatría y adultos. En 2021, se espera que el segmento de adultos muestre un crecimiento significativo porque los estudios demostraron la conexión de esta enfermedad con el envejecimiento.
- Según la vía de administración, el mercado de la nefropatía por IgA se segmenta en oral, parenteral y otros. En 2021, se espera que el segmento oral domine el mercado debido a la amplia variedad de productos orales disponibles en el comercio interestatal por parte del mercado, lo que aumenta el mercado de este segmento.
- On the basis of end user, the IgA nephropathy market is segmented into hospitals, clinics, home healthcare and others. In 2021, hospitals segment is expected to dominate the market due to its strong financial structure.
- On the basis of distribution channel, the IgA nephropathy market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, direct tender segment accelerates the revenue growth as well as provides tax benefits owing to which the direct tender segment is flourishing for the last few years, henceforth, affirmative illustrating the further growth of the market.
Asia-Pacific IgA Nephropathy Market Country Level Analysis
Asia-Pacific IgA nephropathy market is analysed and market size information is provided by the country, disease type, symptoms, type, population type, route of administration, end user and distribution channel as referenced above.
The countries covered in the Asia-Pacific IgA nephropathy market report are the Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam and rest of Asia-Pacific.
Asia-Pacific is expected to grow with the fastest CAGR in the forecast period as in the Asia-Pacific’s countries, the demand for IgA nephropathy is increasing because of the rising demand for IgA nephropathy products. China is expected to dominate the Asia-Pacific IgA nephropathy market as China is one of the leading countries in the Asia-Pacific which utilize advanced IgA nephropathy products and services.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic Initiatives by Manufacturers is creating new opportunities for Players in the IgA Nephropathy Market
The IgA nephropathy market also provides you with detailed market analysis for every country growth. Moreover, it provides detail data regarding growth in IgA nephropathy sales, partnership, acquisition, distribution agreement among the IgA nephropathy market players of Asia-Pacific region. The data is available for historic period 2011 to 2019.
Competitive Landscape and IgA Nephropathy Market Share Analysis
El panorama competitivo del mercado de nefropatía por IgA proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y la extensión de los productos, el dominio de las aplicaciones y la curva de supervivencia de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado de nefropatía por IgA de Asia y el Pacífico.
Los principales actores cubiertos en el informe del mercado de nefropatía por IgA de Asia y el Pacífico son AstraZeneca, Novartis AG, Pfizer Inc., Zydus Cadila, Fresenius Kabi USA (una subsidiaria de Fresenius SE & Co. KGaA), Teva Pharmaceuticals USA, Inc. (una subsidiaria de Teva Pharmaceutical Industries Ltd.), Hikma Pharmaceuticals PLC, LUPIN, Viatris Inc., Siemens Healthcare GmBH (una subsidiaria de Siemens Healthineers AG), Sun Pharmaceutical Industries Ltd., ARKRAY USA, Inc., Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co., Inc., CareDX, Inc., Alembic Pharmaceuticals Limited, Strides Pharma Science Limited, Apotex Inc. entre otros actores nacionales. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Numerosos contratos y acuerdos son iniciados también por empresas de todo el mundo que también están acelerando el mercado de la nefropatía por IgA.
Por ejemplo,
- En octubre de 2020, Viatris Inc., una empresa fusionada de Mylan y Pfizer Inc., recibió la autorización de la Comisión Federal de Comercio de Estados Unidos. Esta aprobación allanó el camino para la creación de una nueva empresa, con énfasis en el desarrollo de medicamentos innovadores y avances para cambiar la vida de los pacientes. Esta aprobación abrió el camino al crecimiento futuro de la empresa.
La colaboración, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando la impresión de la empresa en el mercado de nefropatía por IgA, lo que también proporciona el beneficio para que la organización mejore el crecimiento de sus ventas de nefropatía por IgA.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC IGA NEPHROPATHY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
4.3 CURRENT STUDIES ON ARCHAEOSOMES
5 ASIA-PACIFIC IGA NEPHROPATHY MARKET: COMPETITIVE ENVIRONMENT
6 ASIA-PACIFIC IGA NEPHROPATHY MARKET: REGULATIONS
6.1 THE U.S. REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
6.2 EUROPE REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
6.3 JAPAN REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
7 EPIDEMIOLOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 ASIA-PACIFIC RISE IN IGA NEPHROPATHY DISORDER
8.1.2 1.1.2 INCREASING IGA TARGETED PIPELINE DRUGS
8.1.3 INCREASE RESEARCH & DEVELOPMENT INVESTMENT FOR DRUG DISCOVERY
8.1.4 REIMBURSEMENT PROVIDED FOR KIDNEY DISORDERS
8.1.5 1.1.5 UPCOMING AND RECENT APPROVAL FOR IGA NEPHROPATHY TREATMENT
8.2 RESTRAINTS
8.2.1 HIGH COST OF IGA NEPHROPATHY TREATMENT
8.2.2 DELAYED DIAGNOSIS OF IGA DISORDERS
8.2.3 POOR PLANNING OF IGA NEPHROPATHY TREATMENT IN LOW-INCOME COUNTRIES
8.2.4 INABILITY TO STOP PROGRESSION OF IGA NEPHROPATHY BY CURRENT TREATMENT
8.3 OPPORTUNITIES
8.3.1 COLLABORATION OF MARKET PLAYERS FOR DRUG DEVELOPMENT
8.3.2 GOVERNMENT FUNDING FOR RESEARCH PURPOSE
8.3.3 INCREASE TREND FOR NOVEL DIAGNOSIS PROCEDURE
8.4 CHALLENGES
8.4.1 LOW AWARENESS REGARDING KIDNEY DISEASE
8.4.2 SIDE EFFECT IGA NEPHROPATHY TREATMENT DRUGS
9 IMPACT OF COVID 19 ON THE ASIA-PACIFIC IGA NEPHROPATHY MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT OF DEMAND:
9.3 IMPACT ON SUPPLY CHAIN:
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS:
9.5 CONCLUSION:
10 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 PRIMARY IGA NEPHROPATHY
10.3 SECONDARY IGA NEPHROPATHY
11 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY SYMPTOMS
11.1 OVERVIEW
11.2 HEMATURIA
11.3 PROTEINURIA
11.4 EDEMA
11.5 OTHERS
12 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY TYPE
12.1 OVERVIEW
12.2 DIAGNOSIS
12.2.1 URINE TEST
12.2.1.1 URINE ALBUMIN-TO-CREATININE RATIO
12.2.1.2 DIPSTICK TEST FOR ALBUMIN AND BLOOD
12.2.2 BLOOD TEST
12.2.3 IOTHALAMATE CLEARANCE TEST
12.2.4 KIDNEY BIOPSY
12.2.5 OTHERS
12.3 TREATMENT
12.3.1 BLOOD PRESSURE LOWERING AGENTS
12.3.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
12.3.1.1.1 LISINOPRIL
12.3.1.1.2 ENALAPRIL
12.3.1.1.3 RAMIPRIL
12.3.1.1.4 BENAZEPRIL
12.3.1.1.5 OTHERS
12.3.1.2 ANGIOTENSIN RECEPTOR BLOCKERS (ARBS)
12.3.1.2.1 LOSARTAN
12.3.1.2.2 VALSARTAN
12.3.1.2.3 IRBESARTAN
12.3.1.2.4 OTHERS
12.3.2 IMMUNOSUPPRESANT
12.3.2.1 CYCLOPHOSPHAMIDE
12.3.2.2 AZATHIOPRINE
12.3.2.3 CORTICOSTEROIDS
12.3.2.3.1 METHYLPREDNISONE
12.3.2.3.2 PREDNISOLONE
12.3.2.3.3 OTHERS
12.3.2.4 OTHERS
12.3.3 DIURETICS
12.3.3.1 FUROSEMIDE
12.3.3.2 TORSEMIDE
12.3.3.3 BUMETANIDE
12.3.3.4 OTHERS
12.3.4 LOWER BLOOD CHOLESTEROL
12.3.4.1 ATROVASTATIN
12.3.4.2 SIMVASTATIN
12.3.4.3 ROSUVASTATIN
12.3.4.4 FLUVASTATIN
12.3.4.5 PRAVASTATIN
12.3.4.6 OTHERS
12.3.5 SUPPLEMENTS
12.3.5.1 OMEGA-3-FATTY ACIDS
12.3.5.2 VITAMIN E
12.3.5.3 OTHERS
12.3.6 OTHERS
13 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY POPULATION TYPE
13.1 OVERVIEW
13.2 ADULTS
13.3 CHILDREN
14 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 TABLETS/PILLS
14.2.2 CAPSULES
14.2.3 OTHERS
14.3 PARENTERAL
14.3.1 INTRAVENOUS
14.3.2 INTRAMUSCULAR
14.3.3 OTHERS
14.4 OTHERS
15 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOME HEALTHCARE
15.5 OTHERS
16 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.4 ONLINE PHARMACY
16.5 DIRECT TENDER
16.6 OTHERS
17 ASIA-PACIFIC IGA NEPHROPATHY MARKET BY GEOGRAPHY
17.1 ASIA-PACIFIC
17.1.1 CHINA
17.1.2 JAPAN
17.1.3 INDIA
17.1.4 SOUTH KOREA
17.1.5 AUSTRALIA
17.1.6 SINGAPORE
17.1.7 MALAYSIA
17.1.8 THAILAND
17.1.9 INDONESIA
17.1.10 PHILIPPINES
17.1.11 VIETNAM
17.1.12 REST OF ASIA-PACIFIC
18 ASIA-PACIFIC IGA NEPHROPATHY MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19 SWOT
20 COMPANY PROFILES
20.1 VIATRIS INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 TEVA PHARMACEUTICAL USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE FINANCIALS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 LUPIN
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE FINANCIALS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 ACCORD HEALTHCARE
20.4.1 COMPANY SNAPSHOT
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENTS
20.5 ASTRAZENECA
20.5.1 COMPANY SNAPSHOT
20.5.2 RECENT FINANCIALS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENTS
20.6 PFIZER INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE FINANCIALS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 ZYDUS CADILLA
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE FINANCIALS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENTS
20.8 NOVARTIS AG
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE FINANCIALS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENTS
20.9 ALEMBIC PHARMACEUTICALS LIMITED
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENTS
20.1 STRIDES PHARMA SCIENCE LIMITED
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE FINANCIALS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENTS
20.11 SIEMENS HEALTHCARE GMBH (A SUBSIDIARY OF SIEMENS HEALTHINEERS AG)
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE FINANCIALS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENTS
20.12 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENTS
20.13 HIKMA PHARMACEUTICALS PLC
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
20.14 SUN PHARMACEUTICAL INDUSTRIES LTD.
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE FINANCIALS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT DEVELOPMENT
20.15 APOTEX INC.
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENTS
20.16 ARKRAY USA, INC.
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENTS
20.17 CALIDITAS THERAPEUTICS AB
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE FINANCIALS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENTS
20.18 CAREDX, INC.
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE FINANCIALS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENTS
20.2 OMEROS CORPORATION
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
Lista de Tablas
TABLE 1 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 2 ASIA-PACIFIC PRIMARY IGA NEPHROPATHY IN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 ASIA-PACIFIC SECONDARY IGA NEPHROPATHY IN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC HEMATURIA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC PROTEINURIA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC EDEMA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC OTHERS IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC URINE TEST IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC TREATMENT BY IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC ADUTLS IN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC CHILDREN IN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC PARENTERAL IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC HOSPITALS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 SPECIALTY CLINICS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC HOME HEALTHCARE IN IGA NEPHROPATHY MARKET, BY REGION, 20190-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC HOPSITAL PHARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC RETAIL PHARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC ONLINE PARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC DIRECT TENDER IN IGA NEPHROPATHY MARKET, BY REGION, 2018-2028 (USD MILLION)
TABLE 42 ASIA-PACIFIC OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2018-2028 (USD MILLION)
TABLE 43 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 46 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 ASIA-PACIFIC DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 64 CHINA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 65 CHINA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 66 CHINA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 CHINA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 CHINA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 CHINA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 CHINA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 71 CHINA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 CHINA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 73 CHINA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 CHINA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 CHINA IGA TREATMENT BY DIURETICS IN NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 CHINA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 CHINA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 CHINA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 79 CHINA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 80 CHINA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 CHINA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 CHINA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 83 CHINA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 84 JAPAN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 85 JAPAN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 86 JAPAN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 JAPAN DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 JAPAN DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 JAPAN TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 JAPAN TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 JAPAN TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 JAPAN TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 JAPAN TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 JAPAN TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 JAPAN TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 JAPAN TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 97 JAPAN TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 JAPAN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 99 JAPAN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 100 JAPAN ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 101 JAPAN PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY RPOUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 102 JAPAN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 103 JAPAN IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 104 INDIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 105 INDIA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 106 INDIA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 INDIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 INDIA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 INDIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 INDIA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 INDIA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 INDIA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 INDIA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 INDIA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 INDIA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 INDIA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 117 INDIA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 118 INDIA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 119 INDIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 INDIA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 121 INDIA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 122 INDIA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 123 INDIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 124 SOUTH KOREA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 125 SOUTH KOREA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 126 SOUTH KOREA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 SOUTH KOREA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 SOUTH KOREA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 SOUTH KOREA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 SOUTH KOREA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 SOUTH KOREA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 SOUTH KOREA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 SOUTH KOREA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 SOUTH KOREA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 SOUTH KOREA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 136 SOUTH KOREA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 SOUTH KOREA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 SOUTH KOREA IGA NEPHROPATHY MARKET, BY POPULATION TYPE 2019-2028 (USD MILLION)
TABLE 139 SOUTH KOREA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 140 SOUTH KOREA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 141 SOUTH KOREA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 142 SOUTH KOREA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 143 SOUTH KOREA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 144 AUSTRALIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 145 AUSTRALIA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 146 AUSTRALIA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 AUSTRALIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 AUSTRALIA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 149 AUSTRALIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 150 AUSTRALIA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 151 AUSTRALIA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 152 AUSTRALIA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 153 AUSTRLIA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 AUSTRALIA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 AUSTRLIA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 AUSTRALIA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 AUSTRALIA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 AUSTRALIA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 159 AUSTRALIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 160 AUSTRALIA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 161 AUSTRALIA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 162 AUSTRALIA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 163 AUSTRALIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 164 SINGAPORE IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 165 SINGAPORE IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 166 SINGAPORE IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 167 SINGAPORE DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 168 SINGAPORE DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 169 SINGAPORE TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 170 SINGAPORE TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 171 SINGAPORE TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 SINGAPORE TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 SINGAPORE TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 SINGAPORE TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 SINGAPORE TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 SINGAPORE TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 SINGAPORE TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 SINGAPORE IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 179 SINGAPORE IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 180 SINGAPORE ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 181 SINGAPORE PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 182 SINGAPORE IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 183 SINGAPORE IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 184 MALAYSIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 185 MALAYSIA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 186 MALAYSIA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 187 MALAYSIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 188 MALAYSIA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 189 MALAYSIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 MALAYSIA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 MALAYSIA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 MALAYSIA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 INDIA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 MALAYSIA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 MALAYSIA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 MALAYSIA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 197 MALAYSIA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 198 MALAYSIA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 199 MALAYSIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 200 MALAYSIA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 201 MALAYSIA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 202 MALAYSIA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 203 MALAYSIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 204 THAILAND IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 205 THAILAND IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 206 THAILAND IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 207 THAILAND DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 208 THAILAND DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 209 THAILAND TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 210 THAILAND TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 211 THAILAND TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 212 THAILAND TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 213 THAILAND TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 214 THAILAND TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 215 THAILAND TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 216 THAILAND TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 217 THAILAND TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 218 THAILAND IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 219 THAILAND IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 220 THAILAND ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 221 THAILAND PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 222 THAILAND IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 223 THAILAND IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 224 INDONESIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 225 INDONESIA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 226 INDONESIA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 INDONESIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 228 INDONESIA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 229 INDONESIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 230 INDONESIA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 231 INDONESIA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 232 INDONESIA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 233 INDONESIA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 234 INDONESIA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 235 INDONESIA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 236 INDONESIA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 237 INDONESIA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 238 INDONESIA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 239 INDONESIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 240 INDONESIA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 241 INDONESIA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 242 INDONESIA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 243 INDONESIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 244 PHILIPPINES IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 245 PHILIPPINES IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 246 PHILIPPINES IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 247 PHILIPPINES DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 248 PHILLIPINES DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 249 PHILIPPINES TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 250 PHILIPPINES TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 251 PHILIPPINES TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 252 PHILIPPINES TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 253 PHILIPPINES TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 254 PHILIPPINES TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 255 PHILIPPINES TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 256 PHILIPPINES TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 257 PHILIPPINES TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 258 PHILIPPINES IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 259 PHILIPPINES IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 260 PHILIPPINES ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 261 PHILIPPINES PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 262 PHILIPPINES IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 263 PHILIPPINES IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 264 VIETNAM IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 265 VIETNAM IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 266 VIETNAM IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 267 VIETNAM DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 VIETNAM DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 VIETNAM TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 VIETNAM TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 271 VIETNAM TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 272 VIETNAM TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 273 VIETNAM TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 274 VIETNAM TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 275 VIETNAM TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 276 VIETNAM TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 277 VIETNAM TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 278 VIETNAM IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 279 VIETNAM IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 280 VIETNAM ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 281 VIETNAM PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 282 VIETNAM IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 283 VIETNAM IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 284 REST OF ASIA-PACIFIC IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
Lista de figuras
FIGURE 1 ASIA-PACIFIC IGA NEPHROPATHY MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC IGA NEPHROPATHY MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC IGA NEPHROPATHY MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC IGA NEPHROPATHY MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC IGA NEPHROPATHY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC IGA NEPHROPATHY MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC IGA NEPHROPATHY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC IGA NEPHROPATHY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC IGA NEPHROPATHY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC IGA NEPHROPATHY MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 ASIA-PACIFIC IGA NEPHROPATHY MARKET: SEGMENTATION
FIGURE 12 ASIA-PACIFIC RISE IN IGA NEPHROPATHY DISORDER IS DRIVING THE ASIA-PACIFIC IGA NEPHROPATHY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 PRIMARY IGA NEPHROPATHY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC IGA NEPHROPATHY MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC IGA NEPHROPATHY MARKET
FIGURE 15 IGA NEPHROPATHY BIOPSIES IN DIFFERENT REGIONS
FIGURE 16 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2020
FIGURE 17 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)
FIGURE 18 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY DISEASE TYPE, CAGR (2020-2028)
FIGURE 19 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY SYMPTOMS, 2020
FIGURE 21 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY SYMPTOMS, 2020-2028 (USD MILLION)
FIGURE 22 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY SYMPTOMS, CAGR (2020-2028)
FIGURE 23 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY SYMPTOMS, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY TYPE, 2020
FIGURE 25 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 26 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 27 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2020
FIGURE 29 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 30 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY POPULATION TYPE, CAGR (2020-2028)
FIGURE 31 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 33 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY ROUTE OFADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 34 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 35 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY END USER, 2020
FIGURE 37 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY END USER , 2020-2028 (USD MILLION)
FIGURE 38 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY END USER, CAGR (2020-2028)
FIGURE 39 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 41 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 42 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 43 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC IGA NEPHROPATHY MARKET: SNAPSHOT (2020)
FIGURE 45 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY COUNTRY (2020)
FIGURE 46 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 ASIA-PACIFIC IGA NEPHROPATHY MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 49 ASIA-PACIFIC IGA NEPHROPATHY MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
